Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples